Doctors Link 15-mg Tirzepatide Doses to Anhedonia in 3 Obesity Cases
Updated
Updated · Gizmodo · Jul 16
Doctors Link 15-mg Tirzepatide Doses to Anhedonia in 3 Obesity Cases
3 articles · Updated · Gizmodo · Jul 16
Summary
Three women taking tirzepatide for obesity developed anhedonia-like symptoms after reaching the maximum 15-mg weekly dose, according to a case report published Tuesday in Obesity Pillars.
Dose reduction reversed the problem in all three cases: two patients improved after lowering tirzepatide, while a third regained motivation after restarting at a smaller dose following a temporary stop for a procedure.
Doctors said the effect appears distinct from depression and may stem from GLP-1 drugs modulating dopamine-linked reward circuits in the brain’s ventral tegmental area.
The patients still maintained or continued losing weight after lowering their dose, easing concern that treating the side effect would necessarily undermine obesity therapy.
Authors called the complication rare but worth monitoring at higher doses, especially as tirzepatide and newer GLP-1 drugs are increasingly used beyond weight loss.